SEHK:1088
SEHK:1088Oil and Gas

China Shenhua Energy (SEHK:1088): Valuation Check After Mixed November Coal and Chemical Performance Update

China Shenhua Energy (SEHK:1088) just released its November and year to date operating update, with softer coal volumes but stronger polyethylene and polypropylene sales, giving investors a mixed read on the company’s core and chemical businesses. See our latest analysis for China Shenhua Energy. The stock has been resilient despite softer coal numbers. The latest HK$39.68 close underpins a 21.9% year to date share price return and a standout 36.9% one year total shareholder return,...
SEHK:2282
SEHK:2282Hospitality

Will Elevating Veteran Insider Kenneth Feng To CEO Reshape MGM China Holdings' (SEHK:2282) Macau Narrative

MGM China Holdings has appointed long-serving executive Kenneth Xiaofeng Feng as chief executive officer, effective December 19, 2025, after more than two decades in varied finance, operations and development roles across the MGM group. By elevating its president and executive director, with deep international operations and audit committee experience, to a three-year CEO term, the board is signaling confidence in continuity and execution-focused leadership for its Macau business. We’ll now...
SEHK:1378
SEHK:1378Metals and Mining

Taking Stock of China Hongqiao Group (SEHK:1378) After Its Inclusion in the Hang Seng China Enterprises Index

China Hongqiao Group Added to a Key Benchmark China Hongqiao Group (SEHK:1378) just joined the Hang Seng China Enterprises Index. This shift can pull in institutional money and passive index tracking capital, subtly reshaping the stock’s demand dynamics. See our latest analysis for China Hongqiao Group. The inclusion comes after a powerful run, with the latest share price at HK$31.7 and a year to date share price return of 178.56%, backed by a 1 year total shareholder return of 193.30% that...
SEHK:700
SEHK:700Interactive Media and Services

Tencent (SEHK:700) Valuation Check After Gaming Surge and Nvidia Cloud Workaround Boost Growth Prospects

Tencent Holdings (SEHK:700) is back in focus after China’s video game industry hit a new revenue high, while the company quietly tapped Japanese cloud partners to access Nvidia Blackwell chips despite ongoing US export controls. See our latest analysis for Tencent Holdings. Those themes are already feeding into sentiment, with the share price up strongly on a year to date basis and a solid one year total shareholder return suggesting momentum is still broadly constructive rather than...
SEHK:6682
SEHK:6682Software

Evaluating Beijing Fourth Paradigm Technology (SEHK:6682)’s Valuation After Governance and Board Reforms

Beijing Fourth Paradigm Technology (SEHK:6682) just pushed through a package of governance changes at its December meetings, revising its Articles, refreshing its English name, and adding independent director Pan Jialin to the board. See our latest analysis for Beijing Fourth Paradigm Technology. These governance moves come after a tough stretch, with the latest HK$42.74 quote sitting against a 90 day share price return of minus 34.45% and a 1 year total shareholder return of minus 17.49%...
SEHK:2696
SEHK:2696Biotechs

Shanghai Henlius Biotech (SEHK:2696) Valuation Check After US FDA IND Approval for HLX18 Biosimilar Trial

Shanghai Henlius Biotech (SEHK:2696) just cleared a key hurdle by securing US FDA approval of its IND for HLX18, a nivolumab biosimilar, which paves the way for phase 1 trials in multiple solid tumors. See our latest analysis for Shanghai Henlius Biotech. That HLX18 milestone lands after a busy year for Henlius, with HLX22 plus HLX87 also moving deeper into breast cancer trials. It comes despite a 90 day share price return of minus 19.39 percent and a still eye catching three year total...
SEHK:388
SEHK:388Capital Markets

Hong Kong Exchanges and Clearing (SEHK:388) Valuation Revisited After Liquidity Reforms and Rising Chinese Tech Listing Interest

Hong Kong Exchanges and Clearing (SEHK:388) is back in focus as fresh listing interest from Chinese AI and chipmakers coincides with new liquidity friendly reforms, a mix that could subtly reshape its earnings profile. See our latest analysis for Hong Kong Exchanges and Clearing. The mix of new AI linked listings and liquidity reforms is landing against a backdrop where the latest HK$407 share price reflects a strong year to date share price return. However, the 3 year and 5 year total...
SEHK:2171
SEHK:2171Biotechs

Is BCMA CAR-T Catalogue Inclusion And Pipeline Progress Altering The Investment Case For CARsgen (SEHK:2171)?

CARsgen Therapeutics Holdings recently reported that its BCMA-targeted CAR-T therapy zevorcabtagene autoleucel was added to China’s new Commercial Health Insurance Innovative Drug Catalogue, while early clinical data for its allogeneic BCMA CAR-T candidate CT0596 were presented at the 67th ASH Congress with favorable tolerability and efficacy signals. Together, these updates underline CARsgen’s progress across both approved and next-generation BCMA therapies, signaling broader potential...
SEHK:1308
SEHK:1308Shipping

How Investors May Respond To SITC International (SEHK:1308) One-Off HK$0.70 Special Dividend Announcement

On December 18, 2025, SITC International Holdings Company Limited declared a special dividend of HK$0.70 per share, payable on January 15, 2026, to shareholders on record as of January 12, 2026, with an ex-dividend date of January 5, 2026. This one-off payout, approved following a board meeting convened specifically to consider a special distribution, highlights how management is choosing to return surplus capital to shareholders rather than retain it on the balance sheet. We will now...
SEHK:6990
SEHK:6990Biotechs

Should Kelun-Biotech’s MediLink Settlement and 2026 Framework Deals Reshape SEHK:6990’s Operating Playbook?

Sichuan Kelun-Biotech Biopharmaceutical has called an extraordinary general meeting for 31 December 2025 to approve several 2026 framework agreements covering promotional services, auxiliary R&D support, and procurement and sale of equipment and materials, while also settling trade secret and civil litigation disputes with MediLink Therapeutics through a profit- and income-sharing arrangement. By simultaneously formalising future operating relationships and removing legal uncertainty via the...
SEHK:2142
SEHK:2142Biotechs

HBM Holdings (SEHK:2142): Valuation Check After Bristol Myers Squibb Collaboration Validates Growth Prospects

HBM Holdings (SEHK:2142) just landed a multi year global collaboration and license deal with Bristol Myers Squibb, tying its antibody discovery platform to potentially more than $1.1 billion in future payments. See our latest analysis for HBM Holdings. The market has already started to reprice that validation, with a 1 day share price return of 6.6 percent pushing HBM Holdings to HK$13.34. Its roughly 574 percent year to date share price return and nearly 896 percent 1 year total shareholder...
SEHK:6060
SEHK:6060Insurance

Debt Redemption And Premium Growth Could Be A Game Changer For ZhongAn Online (SEHK:6060)

ZhongAn Online P & C Insurance Co., Ltd. has announced it will redeem all of its remaining US$360,100,000 Notes on January 13, 2026, paying principal plus accrued interest and subsequently delisting the Notes from the Hong Kong Stock Exchange. Alongside this debt redemption plan, the company has reported 5.63% premium income growth driven by health and automobile insurance, and confirmed chairman Yin Hai’s continued leadership, underscoring both operating momentum and governance...
SEHK:916
SEHK:916Renewable Energy

Assessing China Longyuan Power Group (SEHK:916)’s Valuation After Strong November 2025 Renewable Output Growth

China Longyuan Power Group (SEHK:916) just posted upbeat November 2025 production numbers, with total generation up 14% year on year as wind output increased and PV generation rose on continued renewable expansion. See our latest analysis for China Longyuan Power Group. Even with the upbeat November numbers, the share price has been under pressure recently, with a 90 day share price return of minus 12.30%. However, the 5 year total shareholder return of 7.15% suggests the longer term...
SEHK:669
SEHK:669Machinery

A Look at Techtronic Industries (SEHK:669) Valuation as It Winds Down HART to Refocus on Core Brands

Techtronic Industries (SEHK:669) just announced it will wind down its HART business by the end of 2025, keeping the brand but doubling down on Milwaukee and Ryobi in a clear push toward higher margin growth. See our latest analysis for Techtronic Industries. The decision to exit HART comes after a choppy stretch, with a 30 day share price return of 9.29 percent but a year to date share price return of negative 8.66 percent, while the three year total shareholder return remains modestly...
SEHK:1378
SEHK:1378Metals and Mining

Will Index Inclusion in HSCEI Change China Hongqiao Group's (SEHK:1378) Investment Narrative?

In December 2025, China Hongqiao Group Limited was added to the Hang Seng China Enterprises Index, marking its inclusion among major Hong Kong–listed mainland enterprises. This index inclusion can broaden the company’s investor base as passive funds and benchmarked mandates adjust portfolios to reflect the new constituent. We will now explore how Hongqiao’s entry into the Hang Seng China Enterprises Index shapes its investment narrative and perceived market relevance. The end of cancer?...
SEHK:1801
SEHK:1801Biotechs

Innovent Biologics (SEHK:1801): Reassessing Valuation After Landmark Nature Phase 3 Mazdutide Publications

Innovent Biologics (SEHK:1801) just hit a scientific milestone, with two Phase 3 trials of its dual GCG/GLP-1 drug mazdutide published back to back in Nature, sharpening the investment case around its diabetes franchise. See our latest analysis for Innovent Biologics. The latest Nature publications cap a run of positive catalysts, including NRDL additions and Hang Seng index inclusion. This comes even as the 30 day share price return of minus 7.1% contrasts with a powerful 1 year total...